Internal Medicine Alert
RSSArticles
-
Is Screening for Atrial Fibrillation Cost Effective?
Self-screening for atrial fibrillation in elderly individuals could lead to lower stroke rates, prevent bleeding-related hospitalizations, and save money.
-
Fecal Microbiota, live-jslm (Rebyota)
Rebyota can be prescribed to prevent recurring Clostridioides difficile infection for patients age 18 years and older who are following antibiotic treatment for recurring episodes.
-
Is AV Block Complete?
Does the ECG in the figure represent complete AV block? If not, why not?
-
Patients with Chronic Pain and Opioid Misuse: What Treatment Works?
Among primary care patients diagnosed with comorbid chronic pain and opioid misuse, researchers found a specially designed, mindfulness-based group therapy showed superiority to generic supportive group therapy in reducing opioid use and controlling symptoms of chronic pain.
-
Apixaban for Venous Thromboembolism in Patients with End-Stage Kidney Disease
There is a lower risk of bleeding for those taking apixaban during venous thromboembolism treatment compared to warfarin in patients with end-stage kidney disease.
-
Is Routine Stress Testing After Coronary Revascularization Necessary?
A multicentered study of routine stress testing at one year post-percutaneous coronary revascularization compared to usual care in patients with at least one high-risk coronary anatomic or clinical feature failed to show improved clinical outcomes at two years follow-up.
-
It’s Not All About the Cough
Be careful about relying on clinical queries that focus on the presence of cough for two or more weeks, which could lead to delays in the diagnosis of nearly half of pulmonary tuberculosis cases.
-
Teplizumab-mzwv Injection (Tzield)
Teplizumab can be prescribed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients age 8 years and older with stage 2 type 1 diabetes.
-
Is Long-Term Antidepressant Use Hurting Patients?
Long-term antidepressant use could lead to elevated risks of coronary heart disease, along with higher cardiovascular disease mortality and all-cause mortality rates.
-
The Right Dose at the Right Time: Improving Hypertension Outcomes
An online study of evening vs. morning administration of patients’ usual antihypertensive medications, with a median five-year follow-up, revealed there is no difference in major cardiovascular outcomes between the two periods.